The Gross Law Firm Reminds MacroGenics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 24, 2024 - MGNX
Werte in diesem Artikel
NEW YORK, Sept. 9, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of MacroGenics, Inc. (NASDAQ: MGNX).
Shareholders who purchased shares of MGNX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CONTACT US HERE:
https://securitiesclasslaw.com/securities/macrogenics-inc-loss-submission-form-2/?id=100735&from=4
CLASS PERIOD: March 7, 2024 to May 9, 2024
ALLEGATIONS: During the class period, Defendants made material misrepresentations about the safety data from its TAMARACK Phase 2 study of vobramitamab duocarmazine. On May 9, 2024, the investing public learned that the drug was significantly more dangerous than defendants had previously represented. Following this news, MGNX's stock declined 77.4% due to a drop of $11.36/share.
DEADLINE: September 24, 2024 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/macrogenics-inc-loss-submission-form-2/?id=100735&from=4
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of MGNX during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is September 24, 2024. There is no cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
View original content to download multimedia:https://www.prnewswire.com/news-releases/the-gross-law-firm-reminds-macrogenics-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-september-24-2024--mgnx-302241542.html
SOURCE The Gross Law Firm
Ausgewählte Hebelprodukte auf Macrogenics
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Macrogenics
Der Hebel muss zwischen 2 und 20 liegen
Aktuelle Macrogenics Aktie News
Macrogenics Analysen
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Macrogenics nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen
| Datum | Rating | Analyst | |
|---|---|---|---|
| 10.09.18 | Macrogenics Buy | BTIG Research | |
| 05.03.18 | Macrogenics Buy | H.C. Wainwright & Co. | |
| 02.03.17 | Macrogenics Buy | Instinet | |
| 20.12.16 | Macrogenics Buy | SunTrust | |
| 06.08.15 | Macrogenics Buy | Stifel, Nicolaus & Co., Inc. |
